Loading
Life sciences · Journal article
Frontiers in Oncology · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Colorectal cancer (CRC) metastasizes to the ovary in approximately 0.8–7.4% of cases, typically indicating aggressive biology and poor prognosis. Metachronous bilateral ovarian involvement with spontaneous rupture is exceptionally rare, and the distinction between signet-ring cell (Krukenberg) and non-signet-ring cell metastases carries prognostic significance. Case presentation We present a 54-year-old female who underwent laparoscopic right hemicolectomy for pT4aN0M0 ascending colon adenocarcinoma, followed by eight cycles of adjuvant XELOX chemotherapy. Nineteen months later, imaging revealed huge pelvic cystic-solid masses with diffuse peritoneal thickening. Intraoperatively, spontaneous rupture of the mass (~14 cm) with active bleeding and hemorrhagic ascites was found, along with extensive miliary peritoneal seeding. The patient underwent bilateral salpingo-oophorectomy, omentectomy, and HIPEC catheter placement. Pathology confirmed bilateral ovarian metastatic adenocarcinoma of colorectal origin with no signet-ring cells, excluding a true Krukenberg tumor. Genetic testing revealed NRAS p.G12D mutation and high tumor mutational burden (TMB-H). She subsequently received six cycles of XELOX chemotherapy with bevacizumab and serplulimab (anti-PD-1), achieving stable disease. Conclusion This case demonstrates that non-signet-ring cell ovarian metastases can be equally aggressive, manifesting as spontaneous rupture after standardized therapy. For T4a CRC patients with serosal invasion, vigilant surveillance for ovarian and peritoneal metastasis is warranted. The multimodal strategy of cytoreductive surgery, HIPEC, and genotype-directed immunotherapy may offer a promising salvage approach in this challenging setting.